New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 5, 2013
07:45 EDTHZNPHorizon Pharma receives additional U.S. patent allowance for Duexis
Horizon Pharma announced that it has received a Notice of Allowance from the United States Patent and Trademark Office for U.S. Patent Application Serial No. 13/620,150 entitled "Stable Compositions of Famotidine and Ibuprofen" with claims that cover Duexis tablets. Duexis is indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis and to decrease the risk of developing upper gastrointestinal ulcers.
News For HZNP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 7, 2015
10:33 EDTHZNPDepomed says new Horizon proposal 'identical' to prior rejected bid
Subscribe for More Information
09:22 EDTHZNPDepomed resumes, up 40.5% to $29 after Horizon acquisition proposal
Subscribe for More Information
08:45 EDTHZNPDepomed volatility low into Horizon Pharma proposal to acquire
Subscribe for More Information
08:32 EDTHZNPHorizon Pharma to hold a conference call
Subscribe for More Information
08:17 EDTHZNPHorizon Pharma volatility low into proposal to acquire Depomed
Horizon Pharma (HZNP) July call option implied volatility is at 47, August is at 56; compared to its 52-week range of 40 to 100, suggesting low price movement into announcing a proposal to acquire all outstanding shares of Depomed (DEPO) for a per share consideration of $29.25 in an all-stock, tax-free exchange valued at approximately $3B.
07:06 EDTHZNPHorizon Pharma proposes to acquire Depomed for $29.25/share in all-stock deal
Subscribe for More Information
07:04 EDTHZNPHorizon Pharma proposes to acquire Depomed for $29.25/share in all-stock deal
Subscribe for More Information
July 6, 2015
07:10 EDTHZNPHorizon Pharma files patent infringement lawsuits against five companies
Subscribe for More Information
July 2, 2015
07:03 EDTHZNPHorizon Pharma announces USPTO issuance of Notice of Allowance
Subscribe for More Information
June 26, 2015
07:28 EDTHZNPHorizon Pharma price target raised to $40 from $32 at UBS
Subscribe for More Information
June 23, 2015
07:36 EDTHZNPJMP Securities to hold a conference
Subscribe for More Information
07:12 EDTHZNPHorizon Pharma announces notice of allowance with claims covering Ravicti
Horizon Pharma announced that it has received from the United States Patent and Trademark Office a Notice of Allowance for U.S. patent application number 13/775,000, entitled "Methods of Therapeutic Monitoring of Nitrogen Scavenging Drugs" that covers Horizon's U.S. approved product Ravicti Oral Liquid.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use